Bifidobacterium breve strain Yakult + Lactobacillus casei strain Shirota + galactooligosaccharides

Bifidobacterium breve strain Yakult + Lactobacillus casei strain Shirota + galactooligosaccharides is a synbiotic combination consisting of two probiotic bacterial strains (Bifidobacterium breve strain Yakult and Lactobacillus casei strain Shirota, also classified as Lacticaseibacillus paracasei strain Shirota) and the prebiotic galactooligosaccharides (GOS). Developed by Yakult Honsha, this combination is designed to modulate the gut microbiota, increase beneficial bacterial counts, and enhance the production of short-chain fatty acids (particularly acetate) to maintain intestinal environment and barrier function. It is being evaluated in clinical trials as a supportive care therapy (such as Super Synbiotics LBG-P) to prevent infectious complications like enteritis and ventilator-associated pneumonia in critically ill patients with sepsis or severe systemic inflammatory response syndrome (SIRS). It is also under investigation to mitigate chemotherapy-induced adverse events (e.g., diarrhea and febrile neutropenia) in patients with gastric or esophageal cancer, and to improve intestinal function in short bowel syndrome.